UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended August 31, 2004
or
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number 0-17988
Neogen Corporation
(Exact name of registrant as specified in its charter)
Michigan | 38-2364843 | |
(State or other jurisdiction of incorporation or organization) |
(IRS Employer Identification Number) |
620 Lesher Place
Lansing, Michigan 48912
(Address of principal executive offices including zip code)
(517) 372-9200
(Registrants telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. YES x NO ¨
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12B 2 of the Exchange Act). YES x NO ¨
As of October 1, 2004, there were 8,090,000 outstanding shares of Common Stock.
NEOGEN CORPORATION AND SUBSIDIARIES
TABLE OF CONTENTS
Page No. | ||
Item 1. Interim Consolidated Financial Statements (unaudited) |
||
Consolidated Balance Sheets - August 31, 2004 and May 31, 2004 |
1 | |
Consolidated Statements of Income Three months ended August 31, 2004 and 2003 |
2 | |
Consolidated Statements of Stockholders Equity Three months ended August 31, 2004 |
3 | |
Consolidated Statements of Cash Flows Three months ended August 31, 2004 and 2003 |
4 | |
Notes to Interim Consolidated Financial Statements August 31, 2004 |
5 | |
Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations |
8 | |
Item 3. Quantitative and Qualitative Disclosures About Market Risk |
11 | |
Item 4. Controls and Procedures |
12 | |
Item 1. Legal Proceedings |
12 | |
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds |
12 | |
Item 3. Defaults Upon Senior Securities |
12 | |
12 | ||
Item 5. Other Information |
12 | |
Item 6. Exhibits |
12 | |
CEO Certification |
||
CFO Certification |
||
Section 906 Certification |
PART I FINANCIAL INFORMATION
ITEM 1. Interim Consolidated Financial Statements (Unaudited)
NEOGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
August 31, 2004 |
May 31, 2004 | |||||
(In thousands, except share and per share amounts) | ||||||
ASSETS |
||||||
CURRENT ASSETS |
||||||
Cash |
$ | 1,554 | $ | 1,365 | ||
Marketable securities |
31 | 331 | ||||
Accounts receivable, less allowance of $ 563 and $ 571 |
10,357 | 9,924 | ||||
Inventories |
12,383 | 12,374 | ||||
Deferred income taxes |
651 | 651 | ||||
Prepaid expenses and other current assets |
1,266 | 1,630 | ||||
TOTAL CURRENT ASSETS |
26,242 | 26,275 | ||||
NET PROPERTY AND EQUIPMENT |
11,328 | 10,952 | ||||
OTHER ASSETS |
||||||
Goodwill |
18,617 | 18,617 | ||||
Other non-amortizable intangible assets |
675 | 675 | ||||
Other non-current assets, net of accumulated amortization of $ 935 and $ 864 |
3,371 | 3,456 | ||||
$ | 60,233 | $ | 59,975 | |||
LIABILITIES AND STOCKHOLDERS EQUITY |
||||||
CURRENT LIABILITIES |
||||||
Accounts payable |
$ | 2,829 | $ | 3,063 | ||
Accrued compensation |
1,126 | 1,220 | ||||
Federal income taxes |
193 | | ||||
Other accruals |
1,338 | 1,373 | ||||
TOTAL CURRENT LIABILITIES |
5,486 | 5,656 | ||||
LONG-TERM DEBT |
2,400 | 3,900 | ||||
OTHER LONG-TERM LIABILITIES |
2,551 | 2,577 | ||||
STOCKHOLDERS EQUITY |
||||||
Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding |
| | ||||
Common stock, $.16 par value, 20,000,000 shares authorized, 8,086,917 shares issued and outstanding at August 31, 2004; 8,010,222 shares issued and outstanding at May 31, 2004 |
1,294 | 1,282 | ||||
Additional paid-in capital |
26,164 | 25,785 | ||||
Accumulated other comprehensive income |
78 | 99 | ||||
Retained earnings |
22,260 | 20,676 | ||||
TOTAL STOCKHOLDERS EQUITY |
49,796 | 47,842 | ||||
$ | 60,233 | $ | 59,975 | |||
See notes to interim unaudited consolidated financial statements
1
NEOGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
Three Months Ended August 31, | |||||||
2004 |
2003 | ||||||
(In thousands, except per share amounts) | |||||||
Net sales |
$ | 15,212 | $ | 12,233 | |||
Cost of goods sold |
7,707 | 5,973 | |||||
GROSS MARGIN |
7,505 | 6,260 | |||||
OPERATING EXPENSES |
|||||||
Sales and marketing |
3,206 | 2,923 | |||||
General and administrative |
1,151 | 787 | |||||
Research and development |
718 | 676 | |||||
5,075 | 4,386 | ||||||
OPERATING INCOME |
2,430 | 1,874 | |||||
OTHER INCOME (EXPENSE) |
|||||||
Interest income |
2 | 23 | |||||
Interest expense |
(24 | ) | | ||||
Other |
11 | 85 | |||||
(11 | ) | 108 | |||||
INCOME BEFORE INCOME TAXES |
2,419 | 1,982 | |||||
INCOME TAXES |
835 | 680 | |||||
NET INCOME |
$ | 1,584 | $ | 1,302 | |||
NET INCOME PER SHARE |
|||||||
Basic |
$ | .20 | $ | .17 | |||
Diluted |
$ | .19 | $ | .16 | |||
See notes to interim unaudited consolidated financial statements
2
NEOGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)
Common Stock |
Additional Paid-in Capital |
Accumulated Other Comprehensive Income |
Retained Earnings |
Total |
|||||||||||||||
Shares |
Amount |
||||||||||||||||||
(In thousands) | |||||||||||||||||||
Balance, June 1, 2004 |
8,010 | $ | 1,282 | $ | 25,785 | $ | 99 | $ | 20,676 | $ | 47,842 | ||||||||
Exercise of options and warrants |
77 | 12 | 379 | 391 | |||||||||||||||
Comprehensive income: |
|||||||||||||||||||
Net income for the three months ended August 31, 2004 |
1,584 | 1,584 | |||||||||||||||||
Foreign currency translation adjustments |
(21 | ) | (21 | ) | |||||||||||||||
Total comprehensive income |
1,563 | ||||||||||||||||||
Balance, August 31, 2004 |
8,087 | $ | 1,294 | $ | 26,164 | $ | 78 | $ | 22,260 | $ | 49,796 | ||||||||
See notes to interim unaudited consolidated financial statements
3
NEOGEN CORPORATION SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
Three Months Ended August 31, |
||||||||
2004 |
2003 |
|||||||
(In thousands) | ||||||||
OPERATING ACTIVITIES: |
||||||||
Net income |
$ | 1,584 | $ | 1,302 | ||||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: |
||||||||
Depreciation and amortization |
434 | 302 | ||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
(433 | ) | 327 | |||||
Inventories |
(9 | ) | (463 | ) | ||||
Prepaid expenses and other current assets |
364 | (291 | ) | |||||
Accounts payable and accruals |
(170 | ) | (1,264 | ) | ||||
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES |
1,770 | (87 | ) | |||||
CASH FLOWS USED IN INVESTING ACTIVITIES: |
||||||||
Sales of marketable securities |
300 | 18,113 | ||||||
Purchases of marketable securities |
| (18,369 | ) | |||||
Purchases of property and equipment and other assets |
(772 | ) | (313 | ) | ||||
NET CASH USED IN INVESTING ACTIVITIES |
(472 | ) | (569 | ) | ||||
CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES: |
||||||||
Payments on long-term debt |
(1,500 | ) | | |||||
Net proceeds from issuance of common stock |
391 | 135 | ||||||
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES |
(1,109 | ) | 135 | |||||
INCREASE (DECREASE) IN CASH |
189 | (521 | ) | |||||
CASH AT BEGINNING OF PERIOD |
1,365 | 1,061 | ||||||
CASH AT END OF PERIOD |
$ | 1,554 | $ | 540 | ||||
See notes to interim unaudited consolidated financial statements
4
NEOGEN CORPORATION AND SUBSIDIARIES
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENT (UNAUDITED)
1. BASIS OF PRESENTATION
The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles) for interim financial information and with the instructions to Form 10-Q and Article 10 Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the three month period ended August 31, 2004 are not necessarily indicative of the results to be expected for the fiscal year ending May 31, 2005. For more complete financial information, these consolidated financial statements should be read in conjunction with the May 31, 2004 audited consolidated financial statements and the notes thereto included in the Companys annual report on Form 10-K for the year ended May 31, 2004.
2. INVENTORIES
Inventories are stated at the lower of cost, determined on the first-in, first-out method, or market. The components of inventories follow:
August 31, 2004 |
May 31, 2004 | |||||
(In thousands) | ||||||
Raw materials |
$ | 6,135 | $ | 5,487 | ||
Work-in-process |
562 | 526 | ||||
Finished goods |
5,686 | 6,361 | ||||
$ | 12,383 | $ | 12,374 | |||
3. NET INCOME PER SHARE
The calculation of net income per share follows:
Three Months Ended August 31, | ||||||
2004 |
2003 | |||||
(In thousands except per share amounts) | ||||||
Numerator for basic and diluted net income per share: |
||||||
net income |
$ | 1,584 | $ | 1,302 | ||
Denominator: |
||||||
Denominator for basic net income per share - weighted average shares |
8,023 | 7,778 | ||||
Effect of dilutive stock options and warrants |
445 | 433 | ||||
Denominator for diluted net income per share |
8,468 | 8,211 | ||||
Net income per share: |
||||||
Basic |
$ | .20 | $ | .17 | ||
Diluted |
$ | .19 | $ | .16 | ||
On January 2, 2004, the Company paid a 5 for 4 stock split in the form of a stock dividend. All share and net income per share amounts have been retroactively restated to reflect the split as if it took place at the beginning of the periods presented.
5
4. STOCK REPURCHASE
The Companys Board of Directors has authorized the purchase of up to 1,250,000 shares of the Companys Common Stock. As of August 31, 2004, the Company has purchased 871,000 shares in negotiated and open market transactions. Shares purchased under this buy-back program were retired. There were no shares repurchased in the three months ended August 31, 2004 or 2003.
5. SEGMENT INFORMATION
The Company has two reportable segments: Food Safety and Animal Safety. The Food Safety segment produces and markets diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, drug residues, foodborne bacteria, food allergens, pesticide residues, disease infections and levels of general sanitation. The Animal Safety segment is primarily engaged in the production and marketing of products dedicated to animal health, including veterinary instruments and a complete line of consumable products marketed to veterinarians and animal health product distributors. Additionally the Animal Safety segment produces and markets a line of rodenticides to assist in the control of rats and mice in and around agricultural, food production and other facilities.
These segments are managed separately because they represent strategic business units that offer different products and require different marketing strategies. The Company evaluates performance based on total sales and operating income of the respective segments.
Segment information for the three months ended August 31, 2004 and 2003 follow:
Food Safety |
Animal Safety |
Corporate and |
Total | ||||||||||
(In thousands) | |||||||||||||
Fiscal 2005 |
|||||||||||||
Net sales to external customers |
$ | 7,200 | $ | 8,012 | $ | | $ | 15,212 | |||||
Operating income |
1,316 | 1,197 | (83 | ) | 2,430 | ||||||||
Total Assets |
24,787 | 34,764 | 682 | 60,233 | |||||||||
Fiscal 2004 |
|||||||||||||
Net sales to external customers |
$ | 6,899 | $ | 5,334 | $ | | $ | 12,233 | |||||
Operating income |
1,134 | 604 | 136 | 1,874 | |||||||||
Total Assets |
21,574 | 18,550 | 8,092 | 48,216 |
(1) | Includes corporate assets, consisting principally of marketable securities, and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions and minority interests. |
6. STOCK OPTIONS
The Company follows Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock Issued to Employees, in accounting for its stock option plan. Under Opinion No. 25, no compensation expense is recognized because the exercise price of the Companys stock options equals the market price of underlying stock on the date of grant. Had compensation expense for the Companys stock-based compensation plans been determined based on the fair value at the grant dates for awards under those plans consistent with Statement of Financial Accounting Standards (SFAS) No. 123, Accounting for Stock-Based Compensation, the Companys net income and net income per share would have been as follows:
6
6. STOCK OPTIONS (CONTINUED)
Three Months Ended August 31, |
||||||||
2004 |
2003 |
|||||||
(In thousands except per share amounts) |
||||||||
Net income: |
||||||||
As reported |
$ | 1,584 | $ | 1,302 | ||||
Deduct-compensation expense based on fair value method |
(186 | ) | (180 | ) | ||||
Pro forma |
$ | 1,398 | $ | 1,122 | ||||
Basic net income per share: |
||||||||
As reported |
$ | .20 | $ | .17 | ||||
Pro forma |
$ | .17 | $ | .14 | ||||
Diluted net income per share: |
||||||||
As reported |
$ | .19 | $ | .16 | ||||
Pro forma |
$ | .17 | $ | .14 |
7. LEGAL PROCEEDINGS
The Company is subject to certain legal proceedings in the normal course of business that, in the opinion of management, will not have a material effect on its future results of operations or financial position.
8. BUSINESS ACQUISITIONS
On November 21, 2003, Neogen Corporation purchased 100% of the common stock of Hacco, Inc. and of Hess & Clark, Inc. from United Agri Products, Inc. a then wholly owned subsidiary of ConAgra, Inc. Hacco has principal offices in Randolph, Wisconsin, and is a producer of rodenticide products. The Hess & Clark acquisition was principally a product line purchase in which the Company acquired lines of disinfectants and antibacterials.
Consideration for the November 21, 2003 acquisitions was $10,000,000 in cash, including related acquisition costs. Allocation of the purchase price included current assets of $1,800,000; property, plant and equipment of $2,600,000; intangible assets of $7,400,000 (including customer intangibles of $1,900,000; patents and trademarks of $200,000 and goodwill of $5,300,000); and liabilities of $1,800,000, including an environmental remediation liability of $1,200,000. The customer based asset is expected to be amortized over 20 years. The companies are believed to be strong synergistic fits into Neogens overall strategy of providing food and animal safety solutions.
Unaudited pro forma financial information, as if the acquisitions of Hacco and Hess & Clark had taken place on June 1, 2003 is as follows:
Three months ended August 31, 2003 | |||
(In thousands except per share amount) | |||
Revenue |
$ | 14,769 | |
Net income |
$ | 1,517 | |
Diluted net income per share |
$ | .19 |
9. LONG TERM DEBT
The Company has a financing agreement with a bank providing for an unsecured revolving line of credit of $15,000,000. Interest is at prime less 1.25% or Eurodollar prime equivalent, plus 150 basis points at the Companys option (rate elected was 3.0% at August 31, 2004). Financial covenants include maintaining current ratios and debt to earnings ratios (as defined) and specified levels of tangible net worth, all of which are complied with at the balance sheet date. The agreement matures September 1, 2006.
7
ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The information in this Managements Discussion and Analysis of Financial Condition and Results of Operations contains both historical financial information and forward-looking statements. Neogen does not provide forecasts of future performance. While management is optimistic about the Companys long-term prospects, historical financial information may not be indicative of future financial performance.
Safe Harbor and Forward-Looking Statements
Forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, are made throughout this Quarterly Report on Form 10-Q. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words believes, anticipates, plans, expects, seeks, estimates, and similar expressions are intended to identify forward-looking statements. There are a number of important factors, including competition, recruitment and dependence on key employees, impact of weather on agriculture and food production, identification and integration of acquisitions, research and development risks, patent and trade secret protection, government regulation and other risks detailed from time to time in the Companys reports on file at the Securities and Exchange Commission, that could cause Neogen Corporations results to differ materially from those indicated by such forward-looking statements, including those detailed in this Managements Discussion and Analysis of Financial Condition and Results of Operations.
In addition, any forward-looking statements represent managements views only as of the day this Quarterly Report on Form 10-Q was first filed with the Securities and Exchange Commission and should not be relied upon as representing managements views as of any subsequent date. While management may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its views change.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The discussion and analysis of the Companys financial condition and results of operations are based on the consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including those related to receivable allowances, inventories and intangible assets. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
The following critical accounting policies reflect managements more significant judgments and estimates used in the preparation of the consolidated financial statements.
Revenue Recognition
Revenue from sales of products is recognized at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership. This is generally at the time of shipment. Where right of return exists, allowances are made at the time of sale to reflect expected returns based on historical experience.
Accounts Receivable Allowance
Management attempts to minimize credit risk by reviewing customers credit history before extending credit and by monitoring credit exposure on a regular basis. An allowance for possible losses on accounts receivable is established based upon factors surrounding the credit risk of specific customers, historical trends and other information, such as changes in overall changes in customer credit and general credit conditions. Actual collections can differ from historical experience, and if economic or business conditions deteriorate significantly, adjustments to these reserves could be required.
8
Inventory
Obsolete inventory is written off as it is identified against the reserve. Product obsolescence may be caused by shelf-life expiration, discontinuance of a product line, replacement products in the marketplace or other competitive situations. A reserve for obsolescence is established based on an analysis of the inventory taking into account the current condition of the asset as well as other known facts and future plans. The amount of reserve required to record inventory at lower of cost or market may be adjusted as conditions change.
Valuation of Intangible Assets and Goodwill
Management assesses goodwill and other non-amortizable intangible assets for possible impairment on no less often than an annual basis. This test was performed in the fourth quarter of fiscal 2004 and it was determined that no impairment exists. There was also no impairment indicated for 2003. In the event of changes in circumstances that indicate the carrying value of these assets may not be recoverable, management will make an assessment at any time. Factors that could cause an impairment review to take place would include:
| Significant underperformance relative to expected historical or projected future operating results. |
| Significant changes in the use of acquired assets or strategy of the Company. |
| Significant negative industry or economic trends. |
When management determines that the carrying value of intangible assets may not be recoverable based on the existence of one or more of the above indicators of impairment, the carrying value is compared to a value determined based on projected discounted cash flows using a discount rate commensurate with the risk inherent in the Companys current business model. Any impairment identified in this computation is given current recognition in any unissued financial statements. Changes to the discount rate used in the analysis or discounted cash flows can have a significant impact on the results of the impairment test.
RESULTS OF OPERATIONS
Executive Overview
On an overall basis, the Company had a 24% increase in revenues in the August 2004 quarter primarily as a result of revenue increases in the Animal Safety segment. The Animal Safety segments revenue increase of over 50% came principally from the Companys November 2003 acquisition of Hacco, Inc. and Hess & Clark, Inc. Other products increased 5% compared to the August 2003 quarter. Food Safety revenues increased 4% primarily from increases in sales of dehydrated culture media. Favorable weather conditions in the current year resulted in an overall clean harvest. As a result, testing for naturally occurring toxins declined slightly compared to the prior year.
Gross margins were primarily affected by product mix. Operating and net income increased in the quarter as compared to the prior year from the combined effects of the additional sales and from managements continued control of costs.
See the discussions below for more detailed analysis of the results for the Companys operations for the three month period ended August 31, 2004 as compared to the same three month period of the prior year.
9
Three Months Ended August 31, 2004 Compared to Three Months Ended August 31, 2003
Three Months Ended August 31, |
Increase (Decrease) |
||||||||||||
2004 |
2003 |
||||||||||||
(Dollars in Thousands) | |||||||||||||
Food Safety |
|||||||||||||
Natural Toxins & Allergens |
$ | 2,883 | $ | 2,968 | $ | (85 | ) | (2.9 | )% | ||||
Bacteria & General Sanitation |
2,591 | 2,574 | 17 | 0.7 | % | ||||||||
Dehydrated Culture Media & Other |
1,726 | 1,357 | 369 | 27.2 | % | ||||||||
7,200 | 6,899 | 301 | 4.4. | % | |||||||||
Animal Safety |
|||||||||||||
Life Sciences Drug Detections & Vaccines |
1,640 | 1,277 | 363 | 28.4 | % | ||||||||
Rodenticides & Disinfectants |
2,422 | | 2,422 | | |||||||||
Veterinary Instruments & Other |
3,950 | 4,057 | (107 | ) | (2.6 | )% | |||||||
8,012 | 5,334 | 2,678 | 50.2 | % | |||||||||
Total Sales |
$ | 15,212 | $ | 12,233 | $ | 2,979 | 24.4 | % | |||||
Total revenues increased 24% in the August 2004 quarter compared to the August 2003 quarter. Revenues from sales of products related to food safety were up 4% and revenues from animal safety products were up 50%. Exclusive of the sales of products from the businesses purchased in November of 2003, total sales increased 5%.
The increases in sales in the Food Safety segment were primarily related to a 40% increase in sales of dehydrated culture media products. These increases came from increased market penetration of both the domestic and international markets. Increases in sales of bacteria diagnostic products were offset by a 15% decrease in sales of general sanitation products as the Company continued its efforts to shift the sales of these products from a former distributor relationship to internally produced products. The goal of this change to internally produced general sanitation products is to increase gross margins from these sales.
The increases in sales of the Animal Safety segment were primarily related to the sales of the products of Hacco, Inc. and Hess & Clark, Inc. that were purchased in November 2003. Without these acquisitions, other sales increased 5%. Life sciences, drug detection and vaccine products increased 28% principally from strong shipments of vaccine products during the 2004 quarter. Other sales in 2004 were primarily affected by increases in sales of an antiseptic product and a product with periodic supply difficulties offset by decreases in sales of certain products marketed for wound care. Sales of rodenticide products increased 18% in comparison to sales made in the comparable 2003 quarter under former management.
Gross margins in the August 2004 quarter decreased to 49% from 51% in the prior year. Food Safety margins decreased to 57% from 59% in 2004 and Animal Safety gross margins increased to 42% from 41% in the prior year. The overall decrease in gross margin was a result of product mix and the costs of new manufacturing facilities that came on line in first quarter of fiscal 2004 in Lansing and in fourth quarter of fiscal 2004 in Lexington. These new facilities will provide significantly expanded production capability and are expected to provide greater efficiencies in future periods.
Sales and marketing expenses increased by $283,000 in the August 2004 quarter. As a percentage of sales these expenses decreased to 21% of revenues from 24% in the August 2003 quarter. Food Safety sales and marketing expense decreased to 24% from 27% while Animal Safety sales and marketing expense decreased to 19% from 20%. In both divisions strong cost control measures were responsible for the decreases as a percentage of sales. Additionally Animal Safety was positively affected by the relationship between added Hacco sales and added sales marketing expense to service those sales.
General and administrative expenses increased $364,000 from 6% of sales in fiscal 2004 to 8% in the current year. The increased expenses arose primarily from the addition of Hacco as well as expenses related to the increased levels of operations of the Company. In the August 2003 quarter, administrative expenses were credited for reimbursements made by third parties to the Company for legal
10
costs that were previously expensed related to two disputes that were settled during the quarter. Without those legal expense recoveries, general and administrative expense in the August 2003 quarter would have been 9%. In general, the Companys general and administrative expenses are fixed in relationship to revenues.
Research and development expenses in the August 2004 quarter increased $42,000 but declined from 6% of sales in 2004 to 5% in the current year. Although on a quarter to quarter basis, some fluctuations of research and development expense will occur, management expects research and development expense to approximate 5% to 6% of revenues over time. These expenditures approximate 8% to 10% of revenues from products and product lines that are supported by research and development.
Other income decreased significantly in the August 2003 quarter as compared to the prior year. This resulted principally from decreased royalties from related limited partnerships that expired in October 2004. Federal and state income tax rates used in the computation of income tax expense in the periods remained comparable to those in the prior year.
Financial Condition and Liquidity
At August 31, 2004, the Company had $1,585,000 in cash and marketable securities, working capital of $20,756,000 and stockholders equity of $49,796,000. In addition, available bank lines totaled $12,500,000. Cash and marketable securities were substantially unchanged from the balance at May 31, 2004. The Companys cash balance is a factor of drawings on the Companys credit line.
Accounts receivable were $433,000 higher than at May 31, 2004. Days outstanding in account receivables decreased from 58 days at May 31, 2004 to 57 days as of August 31, 2004. Management believes that the recorded allowance is adequate to provide for accounts that may become uncollectable. Inventories at August 31, 2004 were at substantially the same level as at May 31, 2004. The decrease of $170,000 in current liabilities results from the timing of payments.
During the August 31, 2004 quarter, the Company continued to convert a facility in Lansing, Michigan to serve as its principal dehydrated culture media manufacturing operation. The expenditures of approximately $700,000 were financed by cash flows. Additionally, during the quarter operating cash flows were sufficient to provide for repayment of $1.5 million of the Companys long-term credit facility.
Inflation and changing prices are not expected to have a material effect on operations.
Management believes that the Companys existing cash as of August 31, 2004, along with its available bank revolving line of credit and cash expected to be generated from future operations, will be sufficient to fund activities for the foreseeable future. However, existing cash and bank lines may not be sufficient to meet the Companys cash requirements to commercialize products currently under development or its plans to acquire other organizations, technologies or products that fit within the Companys mission statement. Accordingly, the Company may be required to issue equity securities or enter into other financing arrangements for a portion of the Companys future capital needs.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company has minimal interest rate and foreign exchange rate risk exposure and no fixed rate investments or borrowings. The Companys primary interest rate risk is due to potential fluctuations of interest rates for variable rate borrowings.
Generally, sales are denominated in U.S. dollars; however, because Neogen markets and sells its products throughout the world, it could be significantly affected by weak economic conditions in foreign markets that could reduce demand for its products.
Neogen has assets, liabilities and operations outside of the United States that are located primarily in Ayr, Scotland where the function currency is the British Pound. The Companys investment in its foreign subsidiary is considered long-term, accordingly, it does not hedge the net investment or engage in other foreign currency hedging activities due to the insignificance of these balances to the Company as a whole.
11
ITEM 4. CONTROLS AND PROCEDURES
The Companys management, with the participation of the Companys Chief Executive and Chief Financial Officers, has evaluated the effectiveness of the Companys disclosure controls and procedures as of August 31, 2004. Based on that evaluation, the Companys Chief Executive and Chief Financial Officers concluded that the Companys disclosure controls and procedures were effective as of August 31, 2004. There were no material changes to the Companys internal control over financial reporting in the quarter ended August 31, 2004.
The Company is subject to certain legal proceedings in the normal course of business that, in the opinion of Management, will not have effect on its future results of operations or financial position.
Items 2,3,4 and 5 are not applicable and have been omitted.
(a) Exhibit Index
31.1 | Certification of Chief Executive Officer pursuant to Rule 13a 14 (a). | |
31.2 | Certification of Chief Financial Officer pursuant to Rule 13 a 14 (a). | |
32. | Certification pursuant to 18 U.S.C. section 1350 |
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
NEOGEN CORPORATION | ||||
(Registrant) | ||||
Dated: October 11, 2004 |
||||
By: |
/S/ JAMES L. HERBERT | |||
James L. Herbert | ||||
President and Chief Executive Officer | ||||
Dated: October 11, 2004 |
||||
By: |
/S/ RICHARD R. CURRENT | |||
Richard R. Current | ||||
Vice President and Chief Financial Officer |
12